Baylor College of Medicine: Trial Results Show Potential Benefits of Tocilizumab for COVID-19
February 26, 2021
February 26, 2021
HOUSTON, Texas, Feb. 26 (TNSJou) -- The Baylor College of Medicine issued the following news release:
Tocilizumab (TCZ) is one of multiple drugs that have been studied in clinical trials around the world as a potential treatment for COVID-19. A team of international researchers present their results from the COVACTA trial in the New England Journal of Medicine (NEJM).
Baylor College of Medicine was one of the research sites for COVACTA, which evaluated the therapeutic b . . .
Tocilizumab (TCZ) is one of multiple drugs that have been studied in clinical trials around the world as a potential treatment for COVID-19. A team of international researchers present their results from the COVACTA trial in the New England Journal of Medicine (NEJM).
Baylor College of Medicine was one of the research sites for COVACTA, which evaluated the therapeutic b . . .